Not all patients with CLL demand therapy. Irrespective of all the latest developments, the iwCLL continue to recommends watchful observation for individuals with asymptomatic ailment.86 This advice relies on at least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).